Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Shares Issued (2016 - 2025)

Viridian Therapeutics, Inc.\DE has reported Shares Issued over the past 12 years, most recently at $59.5 million for Q4 2025.

  • Quarterly results put Shares Issued at $59.5 million for Q4 2025, down 84.4% from a year ago — trailing twelve months through Dec 2025 was $69.9 million (down 81.79% YoY), and the annual figure for FY2025 was $63.1 million, down 83.55%.
  • Shares Issued for Q4 2025 was $59.5 million at Viridian Therapeutics, Inc.\DE, up from $9.8 million in the prior quarter.
  • Over the last five years, Shares Issued for VRDN hit a ceiling of $381.6 million in Q4 2024 and a floor of -$6.6 million in Q2 2023.
  • Median Shares Issued over the past 5 years was $1.7 million (2024), compared with a mean of $33.1 million.
  • Peak annual rise in Shares Issued hit 940.18% in 2023, while the deepest fall reached 892.2% in 2023.
  • Viridian Therapeutics, Inc.\DE's Shares Issued stood at $32.4 million in 2021, then fell by 25.31% to $24.2 million in 2022, then surged by 351.36% to $109.2 million in 2023, then skyrocketed by 249.35% to $381.6 million in 2024, then crashed by 84.4% to $59.5 million in 2025.
  • The last three reported values for Shares Issued were $59.5 million (Q4 2025), $9.8 million (Q3 2025), and -$1.7 million (Q2 2025) per Business Quant data.